CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26 | +44.4% | 582 | +80.7% | 0.00% | – |
| Q2 2023 | $18 | +80.0% | 322 | +50.5% | 0.00% | – |
| Q1 2023 | $10 | -23.1% | 214 | -32.3% | 0.00% | – |
| Q4 2022 | $13 | -100.0% | 316 | -22.0% | 0.00% | – |
| Q3 2022 | $26,000 | -31.6% | 405 | -35.8% | 0.00% | – |
| Q2 2022 | $38,000 | -97.8% | 631 | -97.7% | 0.00% | -100.0% |
| Q1 2022 | $1,731,000 | -28.1% | 27,580 | -13.2% | 0.01% | -29.4% |
| Q4 2021 | $2,407,000 | +29987.5% | 31,764 | +63428.0% | 0.02% | – |
| Q2 2021 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q1 2021 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q4 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q3 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q2 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q1 2020 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q4 2019 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q3 2019 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q2 2019 | $8,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q1 2019 | $8,000 | – | 50 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |